IL6 and head and neck squamous cell carcinoma: However, a phase II trial in biomarker-unselected patients with cetuximab-resistant recurrent or metastatic HNSCC revealed a specific clinical benefit of dasatinib addition and improved overall survival only among patients with low serum levels of interleukin 6 (IL6) [88].